Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pancuronium is a nondepolarizing neuromuscular blocking agent of the aminosteroid class, used as an adjunct to general anesthesia to facilitate tracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation. It acts as a competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from binding and thereby inhibiting depolarization of muscle fibers. This results in muscle paralysis without causing initial fasciculations. Pancuronium has minimal histamine release but exhibits slight vagolytic activity, which can increase heart rate and blood pressure. Its onset is relatively slow (2–6 minutes), with a long duration of action (up to 100 minutes for clinical effect). The drug’s effects can be reversed by anticholinesterase agents such as neostigmine or pyridostigmine[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pancuronium.